This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Akouos Past Earnings Performance
Past criteria checks 0/6
Key information
-45.4%
Earnings growth rate
75.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -51.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?
Sep 19
Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss
Sep 13We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully
Jun 04We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Feb 19Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth
Oct 28Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation
Jun 26Akouos names Kathy Reape as chief development officer
May 07We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Mar 04Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?
Jan 10Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans
Nov 18Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Akouos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -93 | 26 | 67 |
| 30 Jun 22 | 0 | -96 | 25 | 71 |
| 31 Mar 22 | 0 | -98 | 24 | 74 |
| 31 Dec 21 | 0 | -87 | 22 | 65 |
| 30 Sep 21 | 0 | -74 | 21 | 53 |
| 30 Jun 21 | 0 | -64 | 20 | 45 |
| 31 Mar 21 | 0 | -54 | 17 | 38 |
| 31 Dec 20 | 0 | -49 | 15 | 34 |
| 30 Sep 20 | 0 | -46 | 11 | 35 |
| 30 Jun 20 | 0 | -41 | 7 | 31 |
| 31 Mar 20 | 0 | -30 | 5 | 25 |
| 31 Dec 19 | 0 | -26 | 3 | 20 |
Quality Earnings: AKUS is currently unprofitable.
Growing Profit Margin: AKUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKUS is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare AKUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: AKUS has a negative Return on Equity (-51.2%), as it is currently unprofitable.